MedTrace Logo

Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes

NCT03058029 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2020-07-21

No results posted yet for this study

Summary

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects without or with Type 2 Diabetes

Conditions

Interventions

DEVICE

Gelesis200

Subject would take Gelesis200 capsules 2 times per day.

DEVICE

Placebo

Subject would take placebo capsules 2 times per day.

Sponsors & Collaborators

  • Gelesis, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-22
Primary Completion
2021-01-15
Completion
2021-01-15
FDA Device
Yes

Countries

  • United States
  • Canada
  • Czechia
  • Denmark
  • Hungary
  • Italy
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03058029 on ClinicalTrials.gov